Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: A report from the Swedish National Diabetes Register

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 16, Issue 4, 2009, Pages 506-512

  Nilsson, Peter M ^a   Cederholm, Jan ^b   Eeg Olofsson, Katarina ^d   Eliasson, Björn ^d   Zethelius, Björn ^c   Fagard, Robert ^e   Gudbjörnsdóttir, Soffia ^d  

^a LUND UNIVERSITY   (Sweden)

^b Family Medicine and Clinical Epidemiology Section   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

Author keywords

Cardiovascular diseases; Diabetes; Myocardial infarction; Smoking; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HEMOGLOBIN A;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CIGARETTE SMOKING; COMPARATIVE STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE REGISTRY; FEMALE; FOLLOW UP; GROUPS BY AGE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SMOKING CESSATION; STROKE; SWEDEN;

EID: 70349194930     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32832ccc50     Document Type: Article

References (36)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349:1436-1442.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
3. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993; 306:1313-1318.
4. Canga N, De Irala J, Vara E, Duaso MJ, Ferrer A, Martínez- González MA. Intervention study for smoking cessation in diabetic patients: a randomized controlled trial in both clinical and primary care settings. Diabetes Care 2000; 23:1455-1460.
5. Persson LG, Hjalmarson A. Smoking cessation in patients with diabetes mellitus: results from a controlled study of an intervention programme in primary healthcare in Sweden. Scand J Prim Health Care 2006; 24:75-80.
6. Gritz ER, Vidrine DJ, Fingeret MC. Smoking cessation a critical component of medical management in chronic disease populations. Am J Prev Med 2007; 33 (6 Suppl):S414-S422.
7. Nilsson PM, Gudbjörnsdottir S, Eliasson B, Cederholm J; Steering Committee of the Swedish National Diabetes Register. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes - data from the National Diabetes Register in Sweden. Diabetes Metab 2004; 30:261-268.
8. Gudbjörnsdottir S, Cederholm J, Nilsson PM, Eliasson B, for the Steering Committee of the National Diabetes Register. The National Diabetes Register in Sweden. An implementation of the St. Vincent declaration for quality improvement in diabetes care. Diabetes Care 2003; 26:1270-1276.
9. Nilsson PM, Gudbjörnsdottir S, Eliasson B, Cederholm J, for the Steering Committee of the National Diabetes Register, Sweden. Hypertension in diabetes - trends in control and relation to macrovascular morbidity in repeated national surveys from Sweden. J Hum Hypertens 2003; 17:37-44.
10. Eliasson B, Cederholm J, Nilsson PM, Gudbjörnsdottir S, for the Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996-2003. Diabet Med 2005; 22:1420-1426.
11. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Gudbjörnsdó ttir S, Eliasson B, et al. Overweight, obesity and cardiovascular diseases and mortality in type 2 diabetes: an observational study in 13 087 patients. Diabetologia 2009; 52:65-73.
12. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50:166-174.
13. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, Isacsson SO, et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol 2000; 16 :235-243.
14. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, events rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
15. Spiegelman D, Hertzmark E, Wand HC. Point and interval estimates of partial population attributable risks in cohort studies: examples and software. Cancer Causes Control 2007; 18:571-579.
16. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1990; 316:823-828.
17. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 2001; 101:671-679.
18. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002; 33:1776-1781.
19. Al-Delaimy WK, Manson JE, Solomon CG, Kawachi I, Stampfer MJ, Willett WC, Hu FB. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med 2002; 162:273-279.
20. Nilsson PM, Nilsson J-A ° , Berglund G. Population attributable risk (PAR) of coronary heart disease risk factors during long-term follow-up: the MalmöPreventive Project. J Intern Med 2006; 260:134-141.
21. Schnohr P, Jensen SJ, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002; 23:620-626.
22. Jonsdottir LS, Sigfusson N, Gunason V, Sigvaldason H, Thorgeirson G. Do lipids, blood pressure, diabetes and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 2002; 9:67-76.
23. Health of the people in data tables. Epidemiological Centre, Swedish National Board of Health and Welfare, Stockholm, 2000 (http://www.sos.se).
24. Morrish NJ, Stevens LK, Fuller JH, Jarrett RJ, Keen H. Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 1991; 34:590-594.
25. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3:463-524.
26. Facchini F, Hollenbeck C, Jeppesen J, Chen Y, Reaven G. Insulin resistance and cigarette smoking. Lancet 1992; 339:1128-1130.
27. Wilhelmsen L, Lappas G, Rosengren A. Risk of coronary events by baseline factors during 28 years follow-up and three periods in a random population sample of men. J Intern Med 2004; 256:298-307.
28. Dagenais G, Yi Q, Lonn E, Sleight P, Ostergren J, Yusuf S, on behalf of the HOPE Trial Investigators. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation [HOPE] trial. Eur J Cardiovasc Prev Rehab 2005; 12:75-81.
29. Baba S, Iso H, Mannami T, Sasaki S, Okada K, Konishi M, Shoichiro T, for the JPHC Study Group. Cigarette smoking and risk of coronary heart disease incidence among middle-aged Japanese men and women: the JPHC Study Cohort. Eur J Cardiovasc Prev Rehab 2006; 13:207-213. (Pubitemid 44097725)
30. Tonstad S, Johnston JA. Cardiovascular risks associated with smoking: a review for clinicians. Eur J Cardiovasc Prev Rehab 2006; 13:507-514.
31. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28:88-136.
32. Hokanson JM, Anderson RL, Hennrikus DJ, Lando HA, Kendall DM. Integrated tobacco cessation counseling in a diabetes self-management training program: a randomized trial of diabetes and reduction of tobacco. Diabetes Educ 2006; 32:562-570.
33. Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179:135-144.
34. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
35. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjörnsdottir S, on behalf of the Swedish National Diabetes Register. Risk prediction of cardiovascular disease in type 2 diabetes. Diabetes Care 2008; 31:2038-2043.
36. Lyssenko V, Jonsson A, Pulizzi N, Isomaa B, Tuomi T, Berglund G, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359:2220-2232.